A large number of emerging pathogens, such as severe acute respiratory syndrome (SARS), human immunodeˆciency virus (HIV), and in‰uenza virus are mucosally transmitted and must cross mucosal barriers to infect the host. Thus, to induce a maximal protective eŠect, it is desirable to apply vaccines by the mucosal route where virus infections start. Mucosal vaccines administered either orally or nasally have been shown to be eŠective in inducing antigenspeciˆc immune responses at both systemic and mucosal compartments. However the mucosal antigen-speciˆc immune response is weak because most protein antigens can evoke only a weak immune response when they are applied mucosally. Therefore, one strategy to overcome the weakness of the immune response is a co-administration of mucosal adjuvant with the vaccine antigen. Unfortunately, the development of safe and eŠective mucosal adjuvant has proved to be challenging. Cytokines are promising adjuvants because they are human-derived safe material and display potent immune-modulating functions. In this regards, we have created a mutant tumor necrosis factor a (TNF a ), mTNF K90R, that exhibits high bioactivity and resistance to proteases. In this report, we examined the potential of mTNF K90R as a mucosal adjuvant and evaluated its eŠectiveness and safety.
In in‰uenza studies, BALB/c mice were immunized intranasally with HA together with 1 mg CTB or 5 mg mTNF K90R. One week after the last immunization, HA speciˆc IgG in serum at a 1 : 500 dilution and IgA in nasal or saliva at a 1 : 8 dilution were assessed by ELISA at a 1 : 8 dilution. Data represents the mean of absorbance 450 nm (reference wavelength, 655 nm). N.D.; not detected. Data are presented as means±S.E.M. (n＝4 6;  p＜0.05,   p＜0.01 versus value for HA alone treated group by ANOVA). In HIV studies, BALB/c mice were intranasally immunized with gp120 alone, gp120 plus CTB, or gp120 plus mTNF K90R once a week for four weeks. Serum and mucosal secretions were collected 7 days after the last immunization and analyzed by ELISA for gp120 speciˆc IgA in 8 fold diluted nasal wash or vaginal wash. Data are presented as mean±S.E.M. (n＝6;  p＜0.05). 
